#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

CS

New indication criteria: better availability of GLP1 receptor agonists for our patients

Czech version

Authors: Zbynek Schroner
Authors‘ workplace: Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach
Published in: Diab Obez 2023; 23(45): 61-62
Category:

Labels

Diabetology Obesitology

Quo vadis, slovenská diabetológia?

The dual GIP and GLP1 receptor agonist tirzepatide: a new effective treatment for type 2 diabetes mellitus

Diabetes mellitus and options for early prevention of heart failure

Evaluation of the current situation and possibilities in the management of obesity in Slovakia

Ceramides and cardiovascular disease

Social services in diabetes mellitus

Practical experience with dapagliflozin: case reports

The patient with type 2 diabetes is hemodynamically and metabolically stable, despite treatment, the progression of chronic kidney disease proceeds. What other options do we have? A case report

Empagliflozin in patients with chronic kidney disease: results of the EMPA-KIDNEY trial and implications for clinical practice

The head-to-head comparison of insulin glargine 300 units/ml and degludec 100 units/ml using the CGM technology: results of the InRange trial

The SGLT2 inhibitor canagliflozin: benefits in the treatment of type 2 diabetes mellitus

Spomienka na MUDr. Blaženu Dyskovú

A glimpse into the 13th chamber – overt and covert manifestations of diabetes mellitus

World Diabetes Congress, Lisabon 2022

Advanced Technologies & Treatments for Diabetes 2023, Berlín

5th National SDS Symposium: How are we doing with technology in diabetology in Slovakia and what new things do we expect in the future?

Article was published in

Diabetes a obezita

Issue 45

2023 Issue 45

Most read in this issue

Journals

#ADS_BOTTOM_SCRIPTS#